LivaNova Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Vladimir Makatsaria

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2yrs
Yönetim Kurulu ortalama görev süresi	3.2yrs

Son yönetim güncellemeleri

Recent updates

CEO

Vladimir Makatsaria (51 yo)

less than a year

Görev süresi

Mr. Vladimir A. Makatsaria has been the Chief Executive Officer and Director at LivaNova PLC since March 01, 2024. He is a Non-Executive Director of the Health Products Regulatory Authority Board in Irelan...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Alex Shvartsburg	Chief Financial Officer	4yrs	US$2.77m	0.034% € 929.8k
Michael Hutchinson	Senior VP	2yrs	US$2.07m	0.0042% € 113.5k
Vladimir Makatsaria	CEO & Director	less than a year	Veri yok	Veri yok
Lindsey Little	Senior Director of Investor Relations	no data	Veri yok	Veri yok
Deanna Wilke	Vice President of Corporate Communications	no data	Veri yok	Veri yok
Matthew Dodds	Senior Vice President of Corporate Development & IT	6.8yrs	Veri yok	Veri yok
Paul Buckman	President of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement	no data	Veri yok	Veri yok
Stephanie Bolton	President of Global Epilepsy	4.8yrs	Veri yok	0.018% € 474.7k
Ahmet Tezel	Chief Innovation Officer	less than a year	Veri yok	Veri yok
Franco Poletti	President of Cardiopulmonary Business Unit	less than a year	Veri yok	0.013% € 341.8k
John Webb	Vice President of Sleep Apnea and Epilepsy	no data	Veri yok	Veri yok
Jonathan Walker	VP for Difficult-to-Treat Depression Segment	no data	Veri yok	Veri yok

2.0yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: LIA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Vladimir Makatsaria	CEO & Director	less than a year	Veri yok	Veri yok
Todd Schermerhorn	Independent Non-Executive Director	3.9yrs	US$270.00k	0.011% € 300.6k
Peter Wilver	Independent Director	2.4yrs	US$263.00k	0.0069% € 185.2k
William Kozy	Chairman of Board	6.4yrs	US$3.34m	0.051% € 1.4m
Sharon O'Kane	Independent Non-Executive Director	9.1yrs	US$281.43k	0.017% € 471.2k
Stacy Seng	Independent Non-Executive Director	5.4yrs	US$260.00k	0.016% € 434.0k
Francesco Bianchi	Independent Non-Executive Director	9.1yrs	US$263.00k	0.016% € 435.4k
Susan Podlogar	Independent Director	less than a year	Veri yok	Veri yok
J. Barry	Independent Director	1.1yrs	US$117.88k	Veri yok
Brooke Story	Independent Director	2.2yrs	US$248.00k	0.0064% € 172.5k

3.2yrs

Ortalama Görev Süresi

60.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: LIA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.2 yıldır).

LivaNova Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new directors

LivaNova PLC Appoints Susan Podlogar as New Director

Trui Hebbelinck Leaves Position of LivaNova Plc's Chief Human Resources Officer

Daniel Jeffrey Moore Resigns as Director of LivaNova PLC

LivaNova PLC Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer

LivaNova PLC, Annual General Meeting, Jun 11, 2024

Recent updates

LivaNova PLC Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

Third quarter 2024 earnings released: EPS: US$0.61 (vs US$0.14 loss in 3Q 2023)

High number of new directors

LivaNova PLC Appoints Susan Podlogar as New Director

LivaNova PLC to Report Q3, 2024 Results on Oct 30, 2024

Trui Hebbelinck Leaves Position of LivaNova Plc's Chief Human Resources Officer

Second quarter 2024 earnings released: EPS: US$0.30 (vs US$0.021 in 2Q 2023)

LivaNova PLC Provides Earnings Guidance for the Year 2024

LivaNova PLC to Report Q2, 2024 Results on Jul 31, 2024

Daniel Jeffrey Moore Resigns as Director of LivaNova PLC

LivaNova PLC Provides Update on Recover Clinical Study Evaluating Vns Therapy for Treatment-Resistant Depression in Unipolar Patients

LivaNova PLC Provides Earnings Guidance for the Full-Year 2024

First quarter 2024 earnings released: US$0.78 loss per share (vs US$0.14 profit in 1Q 2023)

LivaNova PLC Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer

LivaNova PLC, Annual General Meeting, Jun 11, 2024

LivaNova PLC to Report Q1, 2024 Results on May 01, 2024

LivaNova PLC Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea

Full year 2023 earnings released: EPS: US$0.33 (vs US$1.61 loss in FY 2022)

Livanova plc Announces Impairment Charges for the Three Month Ended December 31, 2023

LivaNova PLC Announces CEO Changes, Effective on March 1, 2024

LivaNova PLC to Report Q4, 2023 Results on Feb 21, 2024

New minor risk - Earnings quality

Livanova plc Provides Revenue Guidance for the Full-Year 2023

Third quarter 2023 earnings released: US$0.14 loss per share (vs US$2.01 loss in 3Q 2022)

LivaNova PLC Announces Board Changes

Marco Dolci to Retire as President of Cardiopulmonary Business Unit of LivaNova PLC on December 31, 2023

LivaNova PLC to Report Q3, 2023 Results on Nov 01, 2023

LivaNova Unveils Essenz In-Line Blood Monitor with U.S. FDA 510(k) Clearance and CE Mark

LivaNova PLC Provides Financial Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.022 (vs US$0.31 in 2Q 2022)

LivaNova PLC to Report Q2, 2023 Results on Jul 26, 2023

LivaNova PLC Announces 150th Bipolar Depression Patient Randomized in Recover Clinical Study

LivaNova PLC Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings released: EPS: US$0.14 (vs US$0.056 in 1Q 2022)

Full year 2022 earnings released: US$1.61 loss per share (vs US$2.68 loss in FY 2021)

LivaNova PLC Initiates Limited Commercial Release in Europe of the Essenz Perfusion System for Cardiopulmonary Bypass Procedures

LivaNova Launches SenTiva DUO

LivaNova PLC to Report Q4, 2022 Results on Feb 22, 2023

Forecast breakeven date pushed back to 2023

Forecast breakeven date pushed back to 2023

Third quarter 2022 earnings released: US$2.01 loss per share (vs US$0.82 loss in 3Q 2021)

LivaNova PLC Announces Management Changes

LivaNova PLC to Report Q3, 2022 Results on Nov 02, 2022

LivaNova PLC Appoints Brooke Story as New Director

Second quarter 2022 earnings released: EPS: US$0.31 (vs US$1.13 loss in 2Q 2021)

LivaNova PLC Provides Earnings Guidance for the Full Year 2022

LivaNova PLC to Report Q2, 2022 Results on Aug 03, 2022

Now 21% undervalued after recent price drop

LivaNova PLC Announces Executive Changes

LivaNova PLC (NasdaqGS : LIVN) acquired additional 97% majority stake in ALung Technologies, Inc.

First quarter 2022 earnings released: EPS: US$0.056 (vs US$0.61 loss in 1Q 2021)

LivaNova PLC Provides Earnings Guidance for the Full-Year 2022

LivaNova PLC, Annual General Meeting, Jun 13, 2022

LivaNova PLC Initiates Targeted Commercial Launch of the Essenz Patient Monitor for Cardiopulmonary Bypass Procedures

LivaNova Announces First Patient Implanted in OSPREY Clinical Study for Patients Coping with Obstructive Sleep Apnea

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Independent Non-Executive Director recently sold €233k worth of stock

Third quarter 2021 earnings released: US$0.82 loss per share (vs US$0.30 loss in 3Q 2020)

Forecast to breakeven in 2022

LivaNova PLC has completed a Follow-on Equity Offering in the amount of $300.00003 million.

Second quarter 2021 earnings released: US$1.13 loss per share (vs US$1.81 loss in 2Q 2020)

LivaNova PLC Receives FDA Approval for Clinical Study to Evaluate the Aura6000 System to Treat Obstructive Sleep Apnea

Independent Non-Executive Director Hugh Morrison has left the company

Head of Global Operations and R&D recently sold €493k worth of stock

First quarter 2021 earnings released: US$0.61 loss per share (vs US$0.80 profit in 1Q 2020)

LivaNova PLC Reaffirms Sales Guidance for 2021

LivaNova PLC and Verily Announce First Patient Enrolled in Study to Evaluate Treatment Effectiveness for Patients Living with Depression

Full year 2020 earnings released: US$7.07 loss per share (vs US$3.22 loss in FY 2019)

Revenue misses expectations